---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104151"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:39:03.850769+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025

## Summary
- Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.
- Cash and marketable securities $313.4M as of June 30, 2025; runway through 2029.
- BGE-102 IND-enabling completed; Phase 1 SAD/MAD starts 2H 2025 with data by year-end.
- Option agreement for APJ agonist nanobody with >10x apelin potency; oral APJ patent filed.
- Launched HUNT Biobank collaboration to profile 17,000+ samples for aging biology.

## SEC filing metadata
- accession: 0000950170-25-104151
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/0000950170-25-104151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/bioa-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104151
- JSON: https://secwatch.observer/filing/0000950170-25-104151.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.